Non-Absorbable Oral Gentamicin Sulphate: Biopharmaceutical and Dosage Form Evaluation
, , , , , , oraz | 02 kwi 2021
O artykule
Article Category: Original Paper
Data publikacji: 02 kwi 2021
Zakres stron: 8 - 15
Otrzymano: 20 lip 2020
Przyjęty: 07 lut 2021
DOI: https://doi.org/10.2478/afpuc-2020-0016
Słowa kluczowe
© 2021 Nwakile Dozie C. et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Formula for the production of different batches of gentamicin sulphate oral capsules.
| Gentamicin sulphate | 250 | 250 | 250 |
| Carb-o-sil® | 15 | 15 | 15 |
| N-starch | 30 | 30 | 30 |
| Ac-di-sol® | 5 | 5 | 5 |
| PEG 4000 | 50 | --- | --- |
| PVP | --- | 50 | --- |
| Gelatine powder | --- | --- | 50 |
Inhibition zone diameters (IZDs) of some bacteria for selection for the in vitro permeability study.
| Organism | IZD (mm) | |||
| 13.3±0.6 | 7.0±0.0 | 10.0±0.0 | 3.6±0.6 | |
| 8.0±0.0 | 5.0±0.0 | 2.0±0.0 | 0.0±0.0 | |
| 20.0±0.0 | 14.0±0.0 | 15.7±0.6 | 4.0±0.0 | |
| 6.0±0.0 | 4.0±0.0 | 3.3±0.6 | 0.0±0.0 | |
| 8.0±0.0 | 3.0±0.0 | 3.0±0.0 | 0.0±0.0 | |
Average inhibition zone diameter (IZD) (mm) of gentamicin sulphate after 6 h of oral administration at different concentrations.
| Microorganism | 500 | 14.28 | 10.71 | 7.14 | 3.57 |
| 12.0±0.8 | 6.3±0.5 | 6.0±0.0 | 4.3±0.5 | 0.0±0.0 | |
| 13.3±0.5 | 6.0±0.0 | 6.3±0.5 | 4.0±0.0 | 0.0±0.0 | |
| 15.0±0.8 | 8.0±0.8 | 10.0±0.0 | 8.3±0.5 | 0.0±0.0 | |
| 14.3±0.5 | 10.0±0.8 | 7.0±0.8 | 6.3±0.5 | 0.0±0.0 | |
Baseline gentamicin sulphate dose level using inhibition zone diameter (IZDs) (mm) produced by serum drug level of oral gentamicin sulphate against Staphylococcus aureus.
| 0.0 | 0.0 | 0.0 | 0.0 |
| 0.5 | 0.0 | 7.3±0.6 | 10.3±0.6 |
| 1.0 | 0.0 | 8.7±1.2 | 11.3±0.6 |
| 2.0 | 0.0 | 8.2±1.2 | 12.3±0.6 |
| 3.0 | 0.0 | 7.3±0.6 | 13.0±0.0 |
Inhibition zone diameter (IZDs) (mm) produced by serum drug level of orally co-administered gentamicin sulphate with permeation enhancers against Staphylococcus aureus.
| Drug | 400 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| Drug/PEG 4000 | 400/30 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| Drug/Tween® 80 | 400/15 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| Drug/Kolliphor® 188 | 400/1.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| Drug/Glycerine | 400/1.5 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| Drug/SLS | 400/2 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| Drug/Citric acid | 400/2 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| Drug/Oleic acid | 400/2 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
0.0±0.0 |
| aP. enhancer = | Permeation | enhancer, | SLS = | Sodium | lauryl | sulphate |
Duration of GIT local activity of orally administered gentamicin sulphate.
| 0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| 4 | 2.5±0.7 | 0.0±0.0 | 0.0±0.0 | 2.0±0.0 |
| 6 | 3.5±0.7 | 4.0±0.0 | 2.0±0.0 | 6.0±0.0 |
| 8 |
6.0±0.0 | 4.0±0.0 | 4.0±0.0 | 8.0±0.0 |
| 10 | 3.5±0.7 | 0.0±0.0 | 0.0±0.0 | 4.0±0.0 |
| 12 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| 14 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| 16 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| 18 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |